 Shares of MediWound NASDAQ: MDWD and its development partner, Vericel Corporation NASDAQ: VCEL, are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application. The FDA identified issues related to the Chemistry, Manufacturing, and Controls CMC section of the application and requested that MediWound provide additional CMC information. 